Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients
| العنوان: | Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients |
|---|---|
| المؤلفون: | Ryuhei Okuyama, Kaori Sakaizawa, Hisashi Uhara, Atsuko Ashida |
| المصدر: | Acta Dermato-Venereologica, Vol 97, Iss 10, Pp 1212-1218 (2017) |
| بيانات النشر: | ACTA DERMATO-VENEREOLOGICA, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | 0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, Cell, DNA Mutational Analysis, Programmed Cell Death 1 Receptor, Circulating Tumor DNA, droplet digital PCR, 0302 clinical medicine, Antineoplastic Agents, Immunological, Aged, 80 and over, biology, Melanoma, circulating tumour DNA, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.anatomical_structure, Nivolumab, Treatment Outcome, 030220 oncology & carcinogenesis, RL1-803, Biomarker (medicine), Female, Immunotherapy, Antibody, medicine.symptom, Drug Monitoring, anti-programmedcelldeath-1antibody, Cell-Free Nucleic Acids, Proto-Oncogene Proteins B-raf, Inflammation, NRAS, Dermatology, BRAF, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, anti-programmed cell death-1 antibody, Predictive Value of Tests, Cell Line, Tumor, medicine, Biomarkers, Tumor, melanoma, Humans, Aged, business.industry, dropletdigitalPCR, medicine.disease, circulatingtumourDNA, 030104 developmental biology, Mutation, biology.protein, Cancer research, business, Tomography, X-Ray Computed |
| الوصف: | Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAFmutant or NRASmutant) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2?4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy. Article ACTA DERMATO-VENEREOLOGICA. 97:1212-1218(2018) |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0001-5555 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e4f38153932e0b7316ccb20e4d529eTest https://soar-ir.repo.nii.ac.jp/records/20261Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....73e4f38153932e0b7316ccb20e4d529e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00015555 |
|---|